Independent insurance agency providing property, casualty, liability, life, surety bonds, and group insurance for personal and commercial clients.
MidCap Advisors works with lower middle-market businesses and their owners during pivotal moments that influence long-term direction and value. We provide independent guidance rooted in experience, judgment, and a clear understanding of how decisions today affect outcomes over time.
Successful outcomes involve more than financial considerations alone. They reflect priorities related to leadership, continuity, risk, and legacy. We help clients weigh these factors carefully and move forward with clarity and intention.
Our team has deep experience working within lower middle-market businesses across a range of industries and situations. That background informs how we engage with owners and leadership teams and allows us to bring practical perspective to complex decisions.
Many members of our team are former operators in the industries we serve. We have built, grown, and run businesses ourselves. That experience shapes how we evaluate opportunities, manage risk, and think about execution. It keeps our work focused on what actually works in practice, not just in theory.
We operate across the full lifecycle of a transaction. We advise business owners on sell-side mergers and acquisitions, support buyers through diligence and consulting, and invest our own capital. Having experience as advisors, investors, and operators allows us to anticipate challenges early and guide decisions with a broader perspective.
We invest time at the outset to understand each business at no cost, ensuring the engagement is the right fit. That early work allows us to be prepared, aligned, and thoughtful before decisions are made. Our team remains focused on helping owners make informed choices that support their business, their family, and their long-term goals.
Just like in your business, our people are what make us great
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
NEW YORK, NY – July 29th, 2026 – MidCap Advisors, a leading lower-to middle-market investment bank, announced its role as the exclusive financial
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
Our Vice President, Tony Leonard, was recently quoted in a Wealth Solutions Report article.
Tony addresses how a financial advisor can help their business owner clientele when succession through M&A is a priority. With a CPA, an attorney, a financial advisor, and an experienced investment banker who can provide end-to-end guidance, these parties can supply business owners with the appropriate resources and advice. Together they will ensure a timely and successful closing of their client’s company.
Our Vice President of Healthcare, Our Team, was featured in a Healthcare Business International article that further speculated about Fresenius’ strategy to offload its expansive fertility asset, The Eugin Group, to the M&A market. It is through the courtesy of Healthcare Business International that we can share this information with our audience.
Robert shared insights related to The Eugin Group’s partnerships with prominent IVF clinics across 3 continents, he assessed the overall U.S. M&A market, and he explained the market from an investor’s perspective. Also, with experience as an administrator and CEO of a hospital, Robert observed that even though European hospitals are selling “non-core” fertility assets, U.S. hospitals are not doing the same currently. Robert cited higher concentrations of older patients with critical needs, nurse shortages, and wage demands as possibilities for why hospitals would need liquidity.
Currently in its 90th year of operation, PMA provides commercial and personal lines customers risk management solutions.
“EMG retained MidCap to identify a qualified buyer with the ideal cultural fit while maximizing enterprise value,” said Douglas Hendrickson, Partner at MidCap, who led the deal team along with MidCap Vice Presidents Brandon Bisack and Michael Gorlick, and Analyst Gabriella Walker. “The ideal buyer had to respect EMG’s entrepreneurial vision to operate independently and retain its full staff while availing itself of the advanced technological resources and elevated marketing opportunities an acquisition could provide. SMS checked all the boxes.”
SMS represents top Medicare Supplement, Medicare Advantage, annuity, life, long-term care, and travel insurance in all 50 states. The firm was founded in 1982 and joined parent firm Alliant Insurance Services in 2020.
Most owners frame perpetuation as a price problem. The real variable was settled years earlier, and it has nothing to do with the multiple.
Industry Perspective | A three-part series on internal ownership transfer
By Chad Morgan, Vice President at MidCap Advisors
Sooner or later every privately held agency owner answers the same question: sell to the outside, or pass the torch internally. It feels like a question about value. It is almost never decided there.
Internal perpetuation is the gradual, planned transfer of ownership from the principal to the next generation of operators, usually priced at fair market value and paid for over time out of the agency’s own earnings. It remains the most popular stated plan among independent agency owners, and the one most of them never actually complete.
The shortfall between intention and outcome is wide, and it is worth sitting with. Make no mistake: selling externally is often a tremendous strategic win on its own, fueled by active buyers and highly competitive valuations. However, if an owner’s true goal was an internal transfer, abandoning that plan for an external sale usually points to a failure of preparation. This gap is rarely born of negligence – most owners are simply consumed by the daily demands of running the business – and it tends to show up in the exact same place every time.
Owners obsess over the wrong number. The conversation almost always opens with the valuation delta: the spread between what a consolidator would pay today and what an internal buyer can afford. That spread is real, and in a strong market, it can be material. But it is a distraction from the question that actually governs whether an internal deal survives.
That question is quieter and far less flattering to ask out loud: can this agency produce its profit without you in the building? After-tax profit is the only reliable source of financing for your eventual buyout. If profit cannot be sustained in your absence, no structure, no discount, and no clever note rescues the plan. The deal will close and then quietly come apart.
The share of owners who set out to perpetuate internally and actually finish the job, by most industry estimates. The other three usually discover the constraint too late to fix it.
Here is the reality of transition planning, and the reason this series exists. The internal-versus-external choice is often viewed as a strategic decision made at the moment of exit. In truth, it is the cumulative result of decisions made three, five, even seven years earlier, about who was developed, who was trusted with a book, and whether the agency’s income was ever allowed to detach from the founder’s personal relationships.
By the time an owner sits down to weigh internal against external, the menu of available options has already been written. Building a business takes everything you have; it’s no surprise that developing a successor alongside it can be incredibly demanding.
Selling externally is an excellent and highly lucrative path, often providing the ultimate financial reward for a lifetime of hard work. However, owners who invest in building capable successors early on empower themselves with the luxury of choice. They can confidently pursue whichever path – a premium external sale or an internal legacy – best aligns with their goals when the time comes.
Two tests decide everything, and both are about people, not price. Before a single share should change hands, the incoming owners have to clear two bars:
Note what these questions are not. They are not about loyalty, tenure, or how much someone is liked. They are answered by a demonstrated track record, not by hope or by a flattering self-assessment from the candidate. When both answers are a confirmed yes, perpetuation moves from a contingent maybe to an operational decision about timing and structure. When either is a no, every dollar of valuation analysis is premature.
The valuation delta gets the attention because it is concrete and it can be put in a spreadsheet. The succession-capability question often gets avoided because it is awkward and personal. So the easy number crowds out the hard one. That is precisely backwards, and it is the most expensive habit in the entire process.
An owner who runs the hard test first changes the whole posture of the deal. A defined runway before retirement stops looking like a countdown and starts looking like an asset: time to transition client relationships, time to let successors carry real profit-and-loss responsibility, time to build the track record that finances the buyout. The same five years are either a gift or a trap, depending entirely on which question you answered first.
The choice between perpetuating internally and selling externally is not really a choice between two prices. It is a verdict on work that was done, or not done, long before anyone reached for a calculator. The price gap reflects what the market will pay—often an exceptional reward for the business you have built—but it reveals nothing about whether your team can carry the agency the day you step away.
Get that verdict right, and the structure becomes a matter of execution. Get it wrong – by trying to force an internal deal when the team isn’t ready – and the most elegant deal on paper still fails on contact with reality. In those cases, choosing a strategic external sale instead is the right business decision.
If the people are ready, the next failure point is the money. Most internal deals are designed to be self-funding, paid for out of the profit the new owners’ stake generates. Most also break the one rule that keeps them solvent. There is a single ceiling on annual debt service that, once crossed, collapses perpetuation plans after closing more often than any other cause. We will name it, show why owners blow through it, and explain why a deal that leans on the tax deduction of its own purchase price was doomed before the ink dried.
This content is intended for general informational and educational purposes for independent insurance agency owners and does not constitute legal, tax, or investment advice. Specific decisions should be made in consultation with qualified legal, tax, and financial professionals familiar with your circumstances.
Value Is Created Before the Process Begins: One of the most consistent findings in healthcare M&A is that the practices that achieve the highest valuations are those that invested meaningful time and resources in pre-sale preparation, often 18 to 36 months before formally entering a process. The moment you engage with potential buyers, the narrative is largely set. The financial statements are what they are; the operational profile is established; the payer contracts are in place. Buyers will underwrite what they observe. The highest-leverage moment to influence your valuation outcome is before the process begins, not during it.
The first and most foundational step in pre-sale preparation is establishing clean, audit-ready financial statements. This means separating personal expenses from practice operations, normalizing owner compensation to fair market value, documenting all add-backs with supporting receipts and explanations, and ensuring that your chart of accounts clearly reflects the practice’s underlying economics.
Revenue cycle optimization is one of the most direct paths to EBITDA improvement, and therefore to higher valuation. Practices that reduce claims denial rates, accelerate collections, and eliminate coding errors can capture meaningful incremental revenue without adding clinical volume. Similarly, supply chain renegotiation, staffing ratio optimization, and overhead cost reduction can each add meaningful basis points to EBITDA margins. Practices represented by M&A advisors or investment banks achieved, on average, a 25% higher multiple from buyers, a premium largely attributable to pre-market optimization and competitive process management.
Buyers evaluate practices not just as financial assets but as operating businesses that must continue to generate earnings after closing. A practice where all clinical leadership and patient relationships are concentrated in one or two founding physicians presents a concentration risk that buyers will discount. Building a second tier of physician leadership with younger partners who have long-term agreements, administrative responsibilities, and demonstrated patient loyalty is one of the most durable value creation strategies available to OB/GYN practice owners. This process takes time, which is why starting early matters.
Buyers pay for future earnings, not just historical performance. A practice that can articulate a credible, data-supported growth narrative, whether through geographic expansion, service line addition, provider recruitment, or payer contract improvement, will consistently achieve higher valuations than a comparable practice with no visible growth pathway. Work with your advisors to build a coherent growth model grounded in realistic assumptions and supported by documented market data. This narrative serves as the foundation of the Confidential Information Memorandum (CIM), which drives buyer interest and competitive tension in a formal sale process.
An Investment Thesis Built on Fundamentals: Private equity firms do not allocate capital based on sentiment. They follow predictable, scalable cash flows, recurring revenue, and addressable markets large enough to support platform growth. Women’s health checks every one of those boxes. The global women’s health services market was valued at approximately $41.5 billion in 2022 and is projected to grow at more than 5% annually by 2030. The U.S. OB/GYN services segment alone encompasses a fragmented landscape of thousands of independent practices serving tens of millions of patients, exactly the kind of market structure that private equity consolidation strategies are designed to exploit.
Unlike many healthcare specialties where patient encounters are episodic, OB/GYN practices benefit from long, longitudinal patient relationships. A woman’s relationship with her OB/GYN often begins in early adulthood with preventive and contraceptive care and continues through pregnancy, postpartum care, perimenopause, and beyond. This lifecycle engagement creates a highly predictable revenue base that PE underwriters value. Women visit doctors approximately 33% more frequently than men, generating substantial additional healthcare spending, according to AMB Wealth’s OB/GYN Industry Primer. That recurring, high-frequency visit pattern supports the kind of steady EBITDA generation that private equity sponsors rely on when modeling returns.
Beyond core obstetrics and gynecology, women’s health platforms offer compelling cross-sell opportunities. Platforms are increasingly integrating labs, fertility services, aesthetic medicine, menopause care, behavioral health, and mammography into their service portfolios. According to Physician Growth Partners’ Q1 2025 white paper on women’s health private equity, practices offering ancillary services such as fertility treatment, mammography, and menopause care are experiencing accelerated consolidation activity. The Medical Group Management Association (MGMA) has found that practices that integrate ancillary services generate 15% to 25% higher net revenue per provider than those that do not. For a private equity sponsor underwriting a multi-year hold, each new service line represents both incremental EBITDA and a higher exit multiple.
Demand for OB/GYN services is structurally growing. The average maternal age rose from 23.7 in 1985 to 29.6 in 2024, according to Cascade Partners, driving greater complexity and physician oversight requirements for an increasing share of pregnancies. Meanwhile, the supply side is constrained: the U.S. Health Resources & Services Administration projects a shortage of nearly 9,900 OB/GYNs by 2037. The combination of rising demand and constrained supply creates a durable pricing environment—a dynamic PE investors price favorably in their underwriting models. Over 500 hospitals have closed their obstetric units since 2010, accelerating patient migration to independent and consolidated practices.
With nine major platforms now operating and more capital seeking entry, well-positioned independent practices represent valuable acquisition targets in an increasingly competitive market.
A Market in Motion: The women’s health sector has been one of the most actively consolidated corners of U.S. healthcare for more than a decade. What began as a handful of pioneering transactions in 2013, when Ares Management partnered with Unified Women’s Healthcare to form the first dedicated women’s health platform, has since grown into a robust, competitive landscape featuring nine major private equity-backed platforms operating nationwide. Despite a broader cooling in physician practice M&A volume in 2024, women’s health deal activity remained notably resilient, reflecting continued investor confidence in the specialty’s demographic tailwinds and its capacity for service-line expansion.
According to industry data compiled by Irving Levin Associates, physician practice management transactions declined approximately 14% year-over-year in 2024, with 473 deals completed compared to 537 in 2023. Yet women’s health bucked this broader trend. Key platforms dominating recent activity include Altas Partners and Ares Management (Unified Women’s Healthcare), Shore Capital Partners (Together Women’s Health), BC Partners (Women’s Care Enterprises), Partners Group (Axia Women’s Health), LightBay Capital (Femwell/VitalMD), and Webster Equity Partners (Nova Women’s Health Partners), among others, each continuing to build regional density in concentric markets across the Northeast, Southeast, Midwest, and Southwest. Notably, Axia Women’s Health—formed by Audax Private Equity in 2017 and sold to Partners Group in 2021 in a transaction reported at approximately $800 million, completed 18 add-on acquisitions under Audax alone and remains one of the most acquisitive platforms in the space. Most recently, Nova Women’s Health Partners emerged as the ninth major platform through a late-2024 partnership between WomanCare and Women’s HealthFirst, backed by Webster Equity Partners.
Private equity remains the dominant buyer in physician practice M&A, representing more than 90% of transactions. For OB/GYN practices in 2025, add-on acquisitions, the most common transaction type for independent practices, typically transact at mid-single-digit EBITDA multiples, while platform-ready groups with $5 million or more in normalized EBITDA can command multiples of 10x to 14x. The platform premium is real: practices that cross key EBITDA thresholds, have diversified service lines, and have strong management infrastructure can transition from add-on candidates to platform anchors, earning a 4- to 6-turn premium in the process.
The consolidation wave has important strategic implications for independent OB/GYN owners. As platforms grow larger and their geographic footprints expand, competition for clinical talent intensifies, referral dynamics shift, and payer negotiations increasingly favor larger entities. Physician prices for childbirth services in OB/GYN rose by approximately 15% following consolidation, according to research cited by Becker’s Healthcare, illustrating the pricing leverage that scale confers. Independent practices that delay evaluating their strategic options risk finding themselves at a competitive disadvantage as local markets reach saturation, or alternatively, missing the window of maximum investor interest. Understanding the M&A landscape is no longer optional for OB/GYN owners. It is a strategic imperative.
Heading into 2026, healthcare M&A deal value and volume are expected to strengthen, according to PwC’s annual health industries outlook. For OB/GYN practice owners, the question is not whether consolidation will continue but whether they are positioned to participate on favorable terms.
###
